Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, investigator-blinded, randomized, 12-month, parallel-group, non-inferiority study to compare the efficacy of 1.6 to 2.4 g Asacol (Rm) therapy QD versus divided dose (BID) in the maintenance of remission of ulcerative colitis.

Trial Profile

A multi-center, investigator-blinded, randomized, 12-month, parallel-group, non-inferiority study to compare the efficacy of 1.6 to 2.4 g Asacol (Rm) therapy QD versus divided dose (BID) in the maintenance of remission of ulcerative colitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms QDIEM
  • Sponsors Procter & Gamble

Most Recent Events

  • 18 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 24 Mar 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
  • 24 Mar 2010 Warner Chilcott added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top